Shenzhen Salubris Pharmaceuticals Management

Management criteria checks 4/4

Shenzhen Salubris Pharmaceuticals' CEO is Jie Yan, appointed in Sep 2022, has a tenure of 2.17 years. directly owns 0.012% of the company’s shares, worth CN¥4.24M. The average tenure of the management team and the board of directors is 7.9 years and 7.7 years respectively.

Key information

Jie Yan

Chief executive officer

CN¥1.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	2.2yrs
CEO ownership	0.01%
Management average tenure	7.9yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

CEO

Jie Yan (52 yo)

2.2yrs

Tenure

CN¥1,744,500

Compensation

Mr. Jie Yan had been Deputy General Manager at Shenzhen Salubris Pharmaceuticals Co., Ltd. since October 11, 2013 until September 23, 2022 and has been its Non- Independent Director since February 9, 2018...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jie Yan	GM & Director	2.2yrs	CN¥1.74m	0.012% CN¥ 4.2m
Yun Kong	CFO, Accounting Supervisor & Financial Manager	2.9yrs	CN¥1.31m	no data
Ping Chen	Deputy General Manager	17.4yrs	CN¥963.70k	no data
Jianfeng Yang	Secretary of the Board of Directors & Non Independent Director	17.1yrs	CN¥936.70k	0.011% CN¥ 3.8m
Song Ping Zhao	Deputy General Manager	7.9yrs	CN¥1.05m	0.0075% CN¥ 2.7m
Xie Heng	Chief Medical Officer	no data	no data	no data

7.9yrs

Average Tenure

52yo

Average Age

Experienced Management: 002294's management team is seasoned and experienced (7.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jie Yan	GM & Director	6.8yrs	CN¥1.74m	0.012% CN¥ 4.2m
Jianfeng Yang	Secretary of the Board of Directors & Non Independent Director	14.3yrs	CN¥936.70k	0.011% CN¥ 3.8m
Chenghai Ye	Director	17.4yrs	no data	no data
Sing Ye	Chairman	17.4yrs	CN¥1.55m	no data
Houjia Zhu	Independent Director	3.6yrs	CN¥120.00k	no data
Laiping Liu	Independent Director	4.8yrs	CN¥120.00k	no data
Aizhen Li	Chairman of the Supervisory Board	7.9yrs	no data	no data
Xuegong Wang	Independent Director	2.9yrs	CN¥120.00k	no data
Yangbing Li	Supervisor	7.7yrs	no data	no data

7.7yrs

Average Tenure

52yo

Average Age

Experienced Board: 002294's board of directors are considered experienced (7.7 years average tenure).

Shenzhen Salubris Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Shenzhen Salubris Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 22, 2024

High number of new directors

Shenzhen Salubris Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 18, 2022

Recent updates

New minor risk - Shareholder dilution

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024

Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 2Q 2023)

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

First quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 1Q 2023)

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 22, 2024

Full year 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.58 in FY 2022)

Investor sentiment improves as stock rises 17%

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.095 in 2Q 2022)

Upcoming dividend of CN¥0.50 per share at 1.4% yield

Full year 2022 earnings released: EPS: CN¥0.58 (vs CN¥0.50 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.095 (vs CN¥0.073 in 2Q 2021)

High number of new directors

Shenzhen Salubris Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on April 27, 2022

Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.06 in FY 2020)

Shenzhen Salubris Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 18, 2022

Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Dividend for 2021

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.073 (vs CN¥0.047 in 2Q 2020)

ROSY METRO LIMITED acquired a 13.78% stake in M.A. Med Alliance S.A from Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) for $45 million.

First quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.06 (vs CN¥0.68 in FY 2019)

New 90-day high: CN¥38.86

New 90-day high: CN¥32.23

New 90-day low: CN¥26.64

New 90-day low: CN¥29.41

Third quarter earnings released

New 90-day low: CN¥31.38

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 2 billion in funding

New 90-day high - CN¥41.20

Earnings released

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) completed the acquisition of remaining 15.7% stake in Salubris (Suzhou) Pharmaceutical Co., Ltd. from a group of shareholders.

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age